17:14 EDT Celldex (CLDX) down 12.5% at $21.01 after barzolvolimab study update
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex Halts Barzolvolimab Development for EoE
- Celldex says barzolvolimab study meets primary endpoint, will not advance in EoE
- Celldex’s Barzolvolimab: A Promising EoE Treatment with Significant Market Potential – Buy Rating Justified
- Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses
- Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria